PI
RCUS icon

Putnam Investments’s Arcus Biosciences RCUS Stock Holding History

Putnam Investments’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-131,631
Closed -$2.72M – 1188
2022
Q4 		$2.72M Sell
131,631
-6,999
-5% -$193K ﹤0.01% 669
2022
Q3 		$3.63M Buy
+138,630
New +$3.67M 0.01% 524

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Putnam Investments's RCUS Position: Q1 2023 in Review

Putnam Investments sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 131,631 shares — an estimated $2.72M sold.

Putnam Investments first reported a position in RCUS in Q3 2022 and held it in 2 quarters. The position peaked at $3.63M in Q3 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • Putnam Investments reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • Putnam Investments sold 131,631 Arcus Biosciences shares in Q1 2023, an estimated $2.72M.
  • Putnam Investments first reported a position in Arcus Biosciences in Q3 2022 and held it in 2 quarters.
  • Putnam Investments's Arcus Biosciences position peaked at $3.63M in Q3 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Putnam Investments's 13F filing for Q1 2023, filed 22 May 2023.